ACOA Release: Halifax life sciences firm expands to larger facility, eyes increased global exports

Solid State Pharma Inc. to add new equipment, create intellectual property for pharmaceutical, natural health companies.

May 21, 2019 – Halifax, NS – Atlantic Canada Opportunities Agency
Cutting-edge ideas in life sciences help Atlantic Canadian businesses take advantage of emerging opportunities in the pharmaceutical and natural health products sectors, successfully compete in world markets and grow the local economy. Committed to improving drug effectiveness, Solid State Pharma Inc. is helping companies around the world provide faster and more effective drug treatments to patients.

In just five years, the pharmaceutical research company has outgrown its current space and is moving to a new downtown Halifax location, more than tripling its footprint. Solid State Pharma is purchasing state-of-the-art equipment to outfit the laboratory where it will conduct innovative research to produce new intellectual property. Pharmaceutical and natural health care companies will use this research to patent new drugs, extend the patent life of existing drugs, and lower required dosages. Solid State Pharma will decrease costs for its clients, develop new intellectual property to improve the company’s sustainability, add jobs and grow exports around the globe.

Today, Andy Fillmore, Parliamentary Secretary to the Minister of Canadian Heritage and Multiculturalism and Member of Parliament for Halifax, announced a $700,000 Government of Canada contribution to Solid State Pharma Inc. to support its expansion. The announcement was made on behalf of the Honourable Navdeep Bains, Minister of Innovation, Science and Economic Development and Minister responsible for the Atlantic Canada Opportunities Agency (ACOA).

Economic growth and the creation of good jobs for Atlantic Canadians require innovation and diversification. Support for this project is one way the Government of Canada is working to help businesses scale-up, increase productivity and participate in the innovation economy. Projects like this also contribute to the Atlantic Growth Strategy outcome of long-term economic prosperity in the region.

Quotes:
“In a time of rapid technological change and global interconnectedness, we have an opportunity to leverage our healthcare innovations to achieve even greater impact through advances in pharmaceutical research. Companies like Solid State Pharma are world leaders in this field. These firms are helping Atlantic Canada provide better healthcare to Canadians and people around the world, while generating regional economic wealth and creating highly skilled jobs.”
– The Honourable Navdeep Bains, Minister of Innovation, Science and Economic Development and Minister responsible for ACOA

“The Government of Canada, through the Atlantic Growth Strategy, supports investments in research and initiatives that grow the economy and encourage the commercialization of breakthrough ideas. From its new facility, Solid State Pharma Inc. will continue to conduct cutting-edge research to help optimize drug effectiveness for patients around the world.” – Andy Fillmore, Parliamentary Secretary to the Minister of Canadian Heritage and Multiculturalism and Member of Parliament for Halifax

“Bringing value to the patients, to our community and to our team is the primary driving force at Solid State Pharma. We have had four requests for acquisition by European and Chinese companies but we showed no interest because we want to stay and grow here in Atlantic Canada for many years to come. The ACOA contribution helps us meet our long-term vision, create more highly-paid jobs and increase our export revenue.”
Dr. Mahmoud Mirmehrabi, Founder and President, Solid State Pharma Inc.

Quick Facts:
 Solid State Pharma Inc. is an early-stage life sciences company that specializes in pharmaceutical research and crystal engineering.
 The company partners with many global pharmaceutical companies and earns nearly all of its revenue from out-of-country exports.
 When it incorporated in 2014, Solid State Pharma had one employee, founder Dr. Mahmoud Mirmehrabi. The company currently employs 13 full-time staff, two interns and five consultants. It plans to add 25 highly skilled jobs and 15-20 new intern positions over the next five years.
 Solid State Pharma is receiving a $700,000 repayable contribution through the Regional Economic Growth through Innovation (REGI) program.
 The Business Scale-up and Productivity stream of the REGI program supports businesses at various stages of development, including high-growth firms, to accelerate their growth, help them scale-up and enhance their productivity and competitiveness in both domestic and global markets.
 The REGI program continues to build on the objectives of the Government of Canada’s Innovation and Skills Plan.

Contacts:
Chris Brooks
Director, Communications and Outreach
Atlantic Canada Opportunities Agency
902-426-9417 / 902-830-3839 (cell) chris.brooks@canada.ca

Dr. Mahmoud Mirmehrabi President Solid State Pharma Inc.
902-442-4012 ext 1 Mahmoud@solidstatepharma.com

ENTREVESTOR: Adaptiiv Partners With Italy’s EZB

Read the full Entrevestor article here

Adaptiiv Medical Technologies Inc., the Halifax company that uses 3D printing to improve cancer treatment, has further extended its international reach by partnering with Italian peer Eckert & Ziegler BEBIG, or EZB.

EZB specializes in products used in brachytherapy, which applies radioactive sources directly to or into tumors while sparing the surrounding healthy tissue. For the patient, this means shorter treatment periods, fewer side effects and a faster recovery.

The two companies announced Sunday they will test and align their systems to provide an integrated workflow for cancer centers to create 3D-printed brachytherapy applicators customized to each patient. They believe the collaboration will demonstrate that 3D printing can provide clinically viable solutions that improve treatment and patient care.

“This is a significant milestone for us,” said Adaptiiv CTO Alex Dunphy in the press release.“Collaborating with the team at EZB has allowed us to continue to make significant strides towards improving the standard of care using a patient-specific approach in brachytherapy. The successful alignment of our systems will demonstrate that 3D printing can be used to provide a clinically viable solution in brachytherapy treatment.”

NEWS RELEASE: Halifax firm improves lives and provides faster results with new technology

Alentic Microscience Inc. commercializes its blood diagnostic device for medical settings March 4, 2019 – Halifax, NS – Atlantic Canada Opportunities Agency Cutting-edge ideas in life sciences are reaching the marketplace faster than ever, providing Canadians with less invasive and more effective treatment options that improve patient outcomes. Determined to provide mobile healthcare solutions that give immediate results, Alentic Microscience Inc. has developed a pocket-sized diagnostic device that can generate test results in under five minutes, from any location, using only a drop of blood from a pinprick. Conceived for medical diagnostics, Alentic’s technology was chosen by the Canadian Space Agency to conduct immunological research in real-time aboard the International Space Station. Alentic is now commercializing its technology to be used in hospitals, clinics, veterinary settings or in the field. The device uses patented technology to analyze a tiny quantity of blood, producing high quality blood test results immediately at patient point-of-care. The device can perform different types of tests rapidly, which will improve patient care, reduce wait times, lower costs and increase healthcare efficiencies. Today, Andy Fillmore, Parliamentary Secretary to the Minister of Canadian Heritage and Multiculturalism and Member of Parliament for Halifax, on behalf of the Honourable Navdeep Bains, Minister of Innovation, Science and Economic Development and Minister responsible for the Atlantic Canada Opportunities Agency (ACOA), announced $2,992,162 in Government of Canada support to Alentic Microscience Inc. for the project. This investment builds on commitments made by the Government of Canada and the four Atlantic Provinces to drive economic growth in the region through the Atlantic Growth Strategy, which supports strategic investments that build on the region’s competitive advantages, including its growing innovation ecosystem and skilled workforce. Quotes: “In a time of rapid technological change and global interconnectedness, we have an opportunity to leverage our healthcare innovations to achieve even greater impact through advances in life sciences. With commitment and bold action, Atlantic Canada can be a frontrunner for the country, and the world, in providing quality bio-innovations that attract investment and talent, advance our economic prosperity and provide better healthcare to Canadians.” – The Honourable Navdeep Bains, Minister of Innovation, Science and Economic Development and Minister responsible for ACOA “Alentic’s technology is working to transform traditional patient care with shorter wait times for test results. This innovative tool has the potential to improve the lives of thousands of Canadians, particularly those who have health conditions such as heart disease, anemia and immune disorders, for which frequent blood tests are vital to properly manage these illnesses.” – Andy Fillmore, Parliamentary Secretary to the Minister of Canadian Heritage and Multiculturalism and Member of Parliament for Halifax “All of us at Alentic Microscience are deeply grateful to ACOA for their enabling financial support. This contribution will allow us to achieve critical research, development and commercialization milestones on our path to selling Alentic’s revolutionary diagnostic devices in Canada and abroad. The money further allows us to grow our superb team as we approach market entry.” – Alan Fine, CEO, Alentic Microscience Inc. Quick Facts: • Alentic Microscience is receiving a $2,992,162 repayable contribution through ACOA’s Business Development Program (BDP). • The funding will help create six jobs, including a biological engineer, a software developer and an embedded systems engineer, in addition to maintaining 15 jobs, to help with the planning, detailed design, prototype assembly, testing and clinical trials of new devices. • Alentic’s technology is fully operational for specific cellular analyses currently used in medical and veterinary settings. • In collaboration with Honeywell International Inc., Alentic successfully obtained a multi-million dollar contract with the Canadian Space Agency to develop specific diagnostic tests and a device to monitor astronauts’ immune systems in real time, an important task that was previously impossible. • Alentic Microscience Inc. has been granted ten patents in the United States, one in Canada and one in China, with many more patents in progress. • The BDP primarily assists Atlantic Canadian entrepreneurs who want to start a business, increase productivity or improve operations. • The Business Development Program continues to build on the objectives of the Innovation and Skills Plan, a multi-year strategy to create well-paying jobs for the middle class and those working hard to join it. Associated Links:Bio-Analyzer: Instant biomedical results from space to Earth Contacts: Chris Brooks Director, Communications and Outreach Atlantic Canada Opportunities Agency 902-426-9417 / 902-830-3839 (cell) chris.brooks@canada.ca Alan Fine CEO Alentic Microscience Inc. 902-407-0827 / 902-440-3825 afine@alentic.com]]>